Abstract
The effects of 2,5-di(tert-butyl)-1,4-benzohydroquinone (tBHQ), a synthetic phenolic antioxidant and a blocker of the sarco-endoplasmic ATPase, were evaluated on low and high voltage-activated Ca2+ currents (ICas) with rodent dorsal root ganglion, hippocampal, and motor neurons. In all cell types tested, tBHQ (IC50 = 35 μM) blocked ICa at concentrations used to inhibit sarco-endoplasmic ATPase. This effect was specific to tBHQ because the other sarco-endoplasmic reticulum calcium ATPase pump inhibitors (thapsigargin and cyclopiazonic acid) had no effect. Selective blockade of the N-type current with ω-conotoxin GVIA and of P- (motoneuron) or Q-type currents (hippocampal neuron) with ω-agatoxin IVA indicated that tBHQ inhibited N, P, and Q types of ICa. tBHQ had no effect on nitrendipine-sensitive (L-type) and residual drug-resistant (R-type) ICa, nor on the low voltage-activated T-type ICa. Contrary to neuronal cells, the L-type ICa was inhibited by tBHQ in a differentiated mouse neuroblastoma and rat glioma hybrid cell line. Injection of cDNAs encoding the α1A, α1B, α1C, and α1E subunits into oocytes showed that tBHQ blocked ICas at the level of the pore-forming protein. This effect of tBHQ on ICa should be considered when interpreting results obtained with tBHQ used on neuronal preparations. It also may be useful for developing new strategies for the generation of more potent intracellular calcium transient inhibitors.
Footnotes
- Received June 25, 1999.
- Accepted March 23, 2000.
-
Jean Valmier, Institut National de la Santé et de la Recherche Médicale U-432, Montpellier Université II, CC089, place Eugène Bataillon, 34095, Montpellier, Cedex 5, France. E-mail:jvalmier{at}crit.univ-montp2.fr
-
This study was supported by Institut National de la Santéet de la Recherche Médicale, le Centre National de la Recherche Scientifique, and l'Association Française contre les Myopathies. S.R. and P.C. were supported by l'Association pour la Recherche contre le Cancer and la Ligue Nationale contre le Cancer and le Groupe de Reflexion sur la Recherche Cardiovasculaire.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|